Phase II, open-label, randomised, dose ranging trial to determine the optimal starting dose and the efficacy and safety of patiromer in patients with hyperkalaemia

Trial Profile

Phase II, open-label, randomised, dose ranging trial to determine the optimal starting dose and the efficacy and safety of patiromer in patients with hyperkalaemia

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Sponsors Relypsa
  • Most Recent Events

    • 02 Nov 2013 New trial record
    • 17 Oct 2013 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top